Innovent Biologics
Sells mazdutide, a GLP-1 and glucagon dual agonist licensed from Eli Lilly, in China.
Share price
96.25 HKD
What analysts expect
Strong Buy
Buy100%
Hold0%
Sell0%
Price target for the next 12 months
135 HKDUp 55% compared with the current price
Price now 87.40 HKDAverage targetLowest 118 HKD to highest 150 HKD
18 analysts. Targets from the past three months only. Source: TipRanks, 20 Oct 2026. Targets are opinions and are often wrong.
Business
- Yearly revenue
- 18B HKD
- Yearly profit
- 1.4B HKD
- Company value
- 168B HKD
Revenue and profit for the last twelve months reported.
Peptides in this book
- MazdutideTrials only
Recent news
- 2026-06-29 Pfizer and Innovent GLP-1 drugs pass China insurance preliminary review Reuters
Prices are delayed and figures rounded. Not investment advice.